New triple therapy may boost leukemia remission in seniors
NCT ID NCT07469046
First seen Mar 27, 2026 · Last updated Jun 05, 2026 · Updated 8 times
Summary
This study tests whether adding a third drug (homoharringtonine) to the standard two-drug therapy (venetoclax and azacitidine) helps more older adults with acute myeloid leukemia (AML) achieve remission. About 308 patients aged 60-75 who have not yet been treated will be randomly assigned to receive either the two-drug or three-drug combination. The main goal is to see if the three-drug combo leads to higher rates of complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Contact
Conditions
Explore the condition pages connected to this study.